Subscribe
Home
Issues
Online First
2023
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
2021
December 2021 - Vol 14 No 6
October 2021 - Vol 14 No 5
August 2021 - Vol 14 No 4
June 2021 - Vol 14 No 3
April 2021 - Vol 14 No 2
February 2021 - Vol 14 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Ovarian Cancer
HER2-Negative Breast Cancer
Triple-Negative Breast Cancer
Renal-Cell Carcinoma
Biosimilars
Gastrointestinal Cancer
Non–Small-Cell Lung Cancer
Categories
Conference Correspondent
ASCO 2021 - Breast Cancer
ASCO 2020 - Lung Cancer
ASH 2019 Wrap-Up
ASH 2019 MM
Web Exclusives
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Podcasts
Quick Quiz
CE
Quick Quiz
Quick Quiz: Thyroid Cancer
According to the American Cancer Society, approximately 43,800 individuals (11,860 men and 31,940 women) will be diagnosed with thyroid cancer in the United States in 2022, and approximately 2230 individuals (1070 men and 1160 women) will die from the disease. This cancer originates in the thyroid gland, which is part of the endocrine system that controls heart rate, blood pressure, body temperature, and metabolism by secreting hormones. Thyroid cancer is the twelfth most common cancer in the United States, representing 2.3% of all new cancer cases, and is the seventh most common cancer in women. Although the death rate for thyroid cancer increased slightly (0.6% per year) from 2009 to 2018, this rate has been stabilizing in recent years. How much do you know about thyroid cancer?
Start
Quick Quiz: Lung Cancer
Lung cancer is the second most common cancer in men and women and is the leading cause of cancer-related death. The American Cancer Society estimates that approximately 236,740 new cases of lung cancer (117,910 in men and 118,830 in women) will be diagnosed in 2022 and approximately 130,180 individuals (68,820 men and 61,360 women) will die from the disease. In the United States, the number of new lung cancer cases in men has been declining annually since the mid-1980s. In women, the number of new cases diagnosed each year started declining in the mid-2000s. Between 2009 and 2018, incidence rates dropped 1.4% each year in women compared with 2.8% each year in men. How much do you know about lung cancer?
Start
Quick Quiz: Liver Cancer 2022
Cancer that originates in the liver is known as primary liver cancer. According to the American Cancer Society, approximately 41,260 individuals (28,600 men and 12,660 women) will be diagnosed with primary liver cancer in the United States in 2022, and approximately 30,520 individuals (20,420 men and 10,100 women) will die from the disease. From 1980 to 2015, incidence rates for primary liver cancer have more than tripled, although these rates have stabilized recently, and between 1980 and 2013, the overall liver cancer death rate has more than doubled. How much do you know about primary liver cancer?
Start
Quick Quiz: Prostate Cancer 2022
Aside from nonmelanoma skin cancer, prostate cancer is the most common cancer diagnosed among men in the United States and the second leading cause of death in American men. Most prostate cancers are adenocarcinomas, which begin in the gland cells (the cells that make secretions). In rare cases, other types of cancer develop in the prostate, including small-cell carcinomas, transitional-cell carcinomas, neuroendocrine tumors, and sarcomas. According to the American Cancer Society, approximately 268,490 men will be diagnosed with prostate cancer in the United States, and approximately 34,500 men will die from the disease. How much do you know about prostate cancer?
Start
Quick Quiz: Skin Cancer
Approximately 3.4 million Americans will be diagnosed with skin cancer in 2022, making it the most common form of cancer in the United States. Included in this estimation are patients with basal-cell carcinoma and squamous-cell carcinoma, which are the most common types of skin cancer, as well as patients with melanoma, which accounts for approximately 1% of all skin cancers, but is responsible for a large majority of skin cancer–related deaths. Although the total number and incidence rates of basal-cell carcinoma and squamous-cell carcinoma cannot be precisely determined because reporting to cancer registries is not required, it is estimated that they account for less than 0.1% of patient deaths caused by cancer. However, the American Cancer Society estimates that approximately 99,780 individuals will be diagnosed with melanoma in 2022, and approximately 7650 individuals will die from the disease. How much do you know about skin cancer?
Start
Quick Quiz: Soft Tissue Sarcoma
Soft tissue sarcoma is a rare form of cancer that begins in tissues that connect or support other structures in the body, such as fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues. Although the majority of soft tissue sarcomas originate in the arms or legs, they can also be found in internal organs or the retroperitoneum, the trunk, or the head and neck area. Soft tissue sarcomas are most commonly diagnosed in children, accounting for approximately 15% of all pediatric cancers. According to the American Cancer Society, approximately 13,190 individuals (7590 men and 5600 women) will be diagnosed with soft tissue sarcomas in the United States in 2022, and approximately 5130 individuals (2740 men and 2390 women) will die from the disease. How much do you know about soft tissue sarcomas?
Start
Quick Quiz: National Cancer Survivors Day®
On June 5, 2022, people around the world will celebrate National Cancer Survivors Day
®
, a time set aside to recognize cancer survivors, raise awareness of the ongoing challenges these individuals face because of their disease, and celebrate life. A cancer survivor can be defined as anyone who has a history of cancer, from diagnosis through treatment and the remainder of life. The American Cancer Society, the National Cancer Institute, and many other organizations focus a great deal of their efforts on helping cancer survivors manage any ongoing physical, psychosocial, and functional problems related to their disease and treatments, and promoting cancer survivor health and quality of life. How much do you know about cancer survivorship?
Start
Quick Quiz: Brain and Spinal Cord Tumors
Brain and spinal cord tumors are rare forms of cancer, accounting for approximately 1.3% of all new cancer cases in the United States. The lifetime risk for being diagnosed with a malignant tumor of the brain or spinal cord is <1%. According to the American Cancer Society, approximately 25,050 individuals (14,170 men and 10,880 women) will be diagnosed with malignant tumors of the brain or spinal cord in 2022, and approximately 18,280 individuals (10,170 men and 7570 women) will die from the disease. The overall 5-year survival rate for brain and spinal cord tumors is approximately 36%; 75% for individuals aged <15 years; 72% for individuals aged 15 to 39 years; and 21% for individuals aged >40 years. How much do you know about brain and spinal cord tumors?
Start
Quick Quiz: Testicular cancer
Testicular cancer is a malignancy that most commonly originates in the germ cells of 1 or both of the testicles. Although rare, testicular cancer is one of the most frequently diagnosed cancers in young adult men between the ages of 30 and 39 years. For reasons that have yet to be identified, the incidence rates for testicular cancer has been on the rise for the past several decades, although this increase in rates has slowed in recent years. According to the American Cancer Society, approximately 9910 men in the United States will be diagnosed with testicular cancer in 2022, and approximately 460 will die from the disease. How much do you know about testicular cancer?
Start
Quick Quiz: Kidney Cancer
Kidney cancer, also known as renal cancer, is one of the top 10 most common cancers in both men and women in the United States. According to the American Cancer Society, approximately 79,000 individuals (50,290 men and 28,710 women) will be diagnosed with kidney cancer in 2022, and approximately 13,920 individuals (8960 men and 4960 women) will die from the disease. Kidney cancer is most frequently diagnosed in individuals aged 65 to 74 years, and is uncommon in those younger than 45 years. The incidence of kidney cancer has been increasing for several decades, although this uptick in cases has slowed in recent years. Although experts are not certain what is causing this rise in incidence, many believe that is can be attributed in part to the use more effective scanning techniques, which can detect the disease at an earlier stage. How much do you know about kidney cancer?
Start
Page 1 of 6
1
2
3
4
5
6
View the Latest Issue of TON
Read Issue
Home
Issues
Online First
2023
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
2022
December 2022 - Vol 15 No 6
October 2022 - Vol 15 No 5
August 2022 - Vol 15 No 4
June 2022 - Vol 15 No 3
April 2022 - Vol 15 No 2
February 2022 - Vol 15 No 1
2021
December 2021 - Vol 14 No 6
October 2021 - Vol 14 No 5
August 2021 - Vol 14 No 4
June 2021 - Vol 14 No 3
April 2021 - Vol 14 No 2
February 2021 - Vol 14 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT:
First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Checkmate 9LA
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Ovarian Cancer
HER2-Negative Breast Cancer
Triple-Negative Breast Cancer
Renal-Cell Carcinoma
Biosimilars
Gastrointestinal Cancer
Non–Small-Cell Lung Cancer
Categories
Conference Correspondent
ASCO 2021 - Breast Cancer
ASCO 2020 - Lung Cancer
ASH 2019 Wrap-Up
ASH 2019 MM
Web Exclusives
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Podcasts
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION